Condition
Breast Neoplasms, Triple-Negative
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Completed2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07339176Phase 1Not Yet Recruiting
Intratumoral N17350 in Advanced Solid Tumors
NCT03109080Phase 1CompletedPrimary
Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)
NCT04596150Phase 2Completed
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
Showing all 3 trials